Device for prolonged release of medicinal substance in stomach of ruminants

专利摘要:
Laminate device for the controlled and prolonged release of at least one active agent to an ambient environment comprising at least one core sheet, said core sheet or sheets comprising said agent or agents in a polymer matrix, and, in a preferred embodiment, a porosity enhancing agent in admixture with said agent; said core sheet or sheets being alternately sandwiched or interposed between coextensive inert polymeric films substantially impermeable to said environment and to said agenit or agents, said device being perforated by one or a plurality of macroholes extending through said sheets and said films. In a modification of said device the perimeter edge thereof is coated by an inert polymeric film substantially impermeable to said environment and to said agent or agents. Also included are methods for making such a device.
公开号:SU1602389A3
申请号:SU853853845
申请日:1985-02-05
公开日:1990-10-23
发明作者:Роберт Кардинал Джон
申请人:Пфайзер, Инк (Фирма)；
IPC主号:

专利说明:

Fig .;
The invention relates to veterinary medicine, namely to devices containing medicinal preparations, and can be used in combating parasitic diseases by introducing them into the ruminant stomach.
The aim of the invention is to improve the accuracy of controlling the release of drug vegetation.
FIG. Figure 1 shows a three-layered (sandwich) layered device with non-searched end walls, axonometrics; in fig. 2 - the same, with a partial cut.
The device includes a core sheet 1 with medicated Bei ecTBOM 2 dispersed in it, coated with impervious polymer films 3 on both sides. Through holes 4 are made on the core sheet 1 and polymer films 3.
Devices can have various forms.
Example 1. Morantel-citrate is dispersed as a drug and polymer films from a styrene-vinyl acetate copolymer (EVA) into the core fox of the device.
The layer, content of 60% morantel citrate and 40% EVA (type MI-760 with 19% vinyl acetate content, manufactured by USI Chemicals Co., 99 Park Avenue, New York, UL 10016), is prepared by mixing in a dry form 18,001 kg of morantelsitrate and 12,000 kg of EVA in a 55-gall fiber cement drum rotate (208 L for 30 minutes. It is then crushed at high speed to obtain a mixture that passes through a 0.033 inch (0.0838 cm) sieve and mixed spin the drum for another 30 min.
The mixture obtained is passed through a screw extruder with a single screw with an L: d ratio of 24: 1, a diameter of 1 1/4 inch (3.75 cm) and with three heated zones, the temperatures of which are 88, 102 and 107 s, and screw rotation speed 79 rpm. A 6 inch (15.24 cm) mold is a removable plate with apertures of 0.110 inches (0.279 cm), the temperature of the mold is. The extrusion layer is passed through a three-roller tension assembly with cooling with 1 rollers and collected.
0
five
0
five
about
five
40
45
50
From the sheet obtained in this way, cut into rectangular forms measuring 4x7 inches (10.16 x17.78 cm), which are pressed for 15 seconds under a pressure of 1500 pounds (680 kg) with between two plates up to a thickness of 0.065 inch (1.651 mm), and then re-cut to a size of 4x7 inches (10.16 to 17.78 cm).
Three such sheets of the core layer are immersed in an EVA solution (type MI-760), 100 g of toluene to cover approximately 60% of the surface, and hang in a dark cupboard to dry. The rest of the surface is treated in the same way. The devices are further dried overnight in an oven at 60 ° C, then they are weighed and their thickness is measured. The devices are covered two more ta times with an EVA-toluene solution to obtain a three-fold EVA coating of all surfaces.
Forty holes with a diameter of 4 mm, arranged symmetrically in five rows of eight holes in each, are stamped into each of the devices obtained.
Characteristic data of these devices: are given in Table. one .
EXAMPLE 2 In vitro release of moranthel citrate is carried out using the triple-coated concentric multilayer devices of Example 1. For this purpose, the device containing morantel citrate is placed in a two-liter conical flask, which is exposed to light due to the photosensitivity of morantel citrate. 1700 mp O, 1M phosphate buffer solution (pH 6.5-6.6) and the temperature of the bottle and contents are maintained at 22 ° C. The flask containing the device is shaken at a frequency of 85 deviations of 3 inches (7.62 cm) and periodically taken samples (samples) of 5 MP each. The volume of the sample taken is replaced with an equivalent volume of buffer phosphate solution and shaking of the flask is continued. The morantel concentration in the samples is determined spectrophotometrically by measuring the light absorption measure of the sample at 318 nm compared with fresh buffer phosphate solution (pH 6.5-6.6). The concentration of the drug substance in the spectrophotometric measurement is given in Table. 2
Example 3. SUBSTANCE: release of the drug from the body of cattle.
The devices were prepared according to application 1, but using four rectangular pieces of 1 / 4x7 inches 0.80 x 17.78 cm of the core material, turning into a core layer under a pressure of 1100-1300 pounds (499-590 kg) between the plates installed 4Is from one another at a distance of 0.053 inches (1.346 mm), with and at a dwell time of 15-17 s. The resulting core multilayer sheet is cut to a size of 4x7 inches (10.16x17.78 cm) before immersion in the solution described in example 1 with the exception that the entire sheet is immersed in an EVA solution and the entire surface is coated in one immersion. This immersion process is carried out twice.
The intracellular release of morantelcite using the devices is determined by injecting the two mentioned devices of each of 12 cattle (one year old and weighing 700 pounds (318 kg) with a cannulated scar
(Holstein and Gurnsi). Cattle is fed only with grain silage, supplemented
one pound (0.45 kg) per head. per day supplements containing 32% protein, and hydrated ad libitum.
Horned cattle are divided into four groups of three individuals each and devices from a certain group are extracted after 3, 14, 28 and 45 days, respectively. for analysis on the content of moranteliditrate.
To groups of individuals, the devices from which are removed after 3, 14, and 28 days, two new devices are immediately introduced and removed, respectively, after 91, 60, and 7 days. after The data for isolating the drug are given in table. 3.,
EXAMPLE 4. Devices with various medicinal substances are prepared analogously to example 3, the following drugs are used: moranteltartrate (60%), pyrantelic citrate (75%), pyrantel hydrochloride. (65%), tetramysol-chloro-hydrate (50%), left liver II-hydrochloride (50%), ivermectin (30%), diethylcarbamazine citrate (60%), morantelcitrate (10%, 30%), hydromycin B (30%) .aok
.

ten
15
20
25
thirty
35
40
45
50
55
si1D1klingiklat (30%), epitpom itsin- hlorgkdrat (20%), tiaminhlorgidrat (10%), oksitetratsiklinhlorgidrat (50%) ampicillin sodium salt (45%) neomycin complex (55%), oleandomi- tsinhlorgidrat (30%) lincomycinchloro hydrate (60%), tylosis-hydrochloride (60%), amprolium hydrochloride (70%), N-trityl-morpholine (50%), salinomycin (50%).
Each of the devices thus prepared isolates the drug in the in vitro medium of Example 2 for a long time at a zero speed order.
PRI me R 5. Analogously to example 3, the number of holes and their diameter in devices are examined, and macro-perforations are also obtained analogously to example 3. The data on the number of holes and their diameter in the device are given in table. four.
Each of the above table. 4 devices provide long-lasting isolation of moranthel citrate in vitro and in vivo at an almost constant rate.
Additional devices are made analogously to example 1, but with a preliminary mixing of 1, 7, 000 kg of morantel-: citrate and 11, 325 kg of ECA. Temperatures in: thermal zones of the extruder 88, 1 02 and,
102 s, respectively. The rotation speed of the screw is 60 rpm, the size of the holes in the die is 0.106 in. (0.269 cm). The mixture is fed to the extruder using a feed feeder.
Pieces of 7.4x3.5 inches (18j80x x8.89 cm) are cut from a rectangular sheet, dipped twice into an EVA-toluene solution in Example 3. Coated. CiTiaT clumps overnight in a hood, and then punched through each device holes with a diameter of 2.7 mm using a single punching in vitro pneumatically actuated device. Relevant characteristics. received devices are given in table. five.
. In vitro release of moranthelcite-. Data using the proposed devices is determined as follows.
The device is placed .in 750-mshshi-
meter bottle of dark glass with 550 ml of 0.1 M phosphate buffer solution (pH 6.5 - 6.6). The bottle is placed in a thermostated shaken bath maintained at 37 ° C. and shaken at a frequency of 60 deflection 160238
Scientific research institute on 3 inches (7,6 cm) n 1 min. Samples are taken periodically and the volume of the sample withdrawn is replaced with an equal volume of phosphate buffer solution and shaking is continued. The concentration of moranthan in the samples is determined spectrophotometrically by measuring the light absorption measure at 318% compared to light phosphate, 1m buffer rast
ten

a thief (pH 6.6)
ten
25
Morantelpitratus freezes are listed in Table 6.
PRI meR 6. The device is manufactured and the rate of drug release is examined.
An ioanteltartrate and EVA, analogously to example 1, are mixed by a mixture / grinding / mixture method using a rotating drum and a melon, at medium speed to obtain a mixture containing 50 / 5P (Mae / May) mixtures of these materials. From this mixture, a layer is formed using a Banbury mixer, and then precipitate out as small particles for extrusion. This material is extruded at a temperature in zones 88, 965, respectively, and at a mold temperature of 105 ° C. The rotational speed of the screw is 40 rpm, the sheet obtained has a volume of 0.060 inch (0.152 cm) and cyrine 6 inches (15.24 cm). The material after the extruder is cut into sheets of 8.15 in. (20.70 cm) and 3.72 in. 1 tsirina (9.45 cm) and coated by dipping three times in a 10% solution of EVA in toluene, and then dried 50 ° P, The average value of the initial drug load for this device is 11.27 g. Through each sheet ninety-two holes with a diameter of 2.7 mm are symmetrically pushed through.
thirty
40
The in vitro release rate of these sheets is determined in accordance with the procedure of Example 2. The data are given in Table. 7,
The data for determining the in vivo release rate in accordance with the procedure of Example 3 is given in Table 8.
 PRI me e. P 7. The device containing porozigena
Device5 containing 50%., 49.9% lactose and 0.1% (May / May.) Ec-radiolad is prepared by mixing the ingredients in a plastic bag for 30 minutes. Received
eight
-
0
five
0
five
0
0
five
0
five
the mixture is passed through an extruder described in example 1, with heating TpeNW 3OHaMii to temperatures of 93, 99, 110 ° C and with a mold temperature of 99 ° C. The screw rotates at 40 rpm and the tension roller at 0.93 rpm.
The sheet obtained in the extruder has a width of 0.075 inches (0.191 cm) and a width of approximately 6 inches (15.24 cm). Rectangular pieces of 5x10 inches (12.70x25.40 cm) are cut from this sheet, and both surfaces are covered with an EVA film — polyethylene — 0.0025 inches thick (0.00635 cm) using a Carver heating press. Two hundred are punched into each sheet. holes with a diameter of 2.5 mm. The rate of release of the lush is determined by high-performance liquid chromatography using a column C, d as the reversible phase and a mixture of methanol and water (80:20) as the mobile.
Devices (perforated sheets) are placed in a solution containing 0.5% sodium lauryl sulfate, which is continuously shaken in a bath maintained at 38 ° C. The concentration of the drug is always less than 10% of the equilibrium solubility of the drug in solution. Experimental data on the release of extradiol are given in Table 9.
PRI me R 8. Device for rapid release of amypigscillin.
A mixture of 30.34 g of EVA (analogous to example 1) and 45.08 g of sodium and food is mixed in a flask for 30 minutes. The mixture is placed in a mold made from an aluminum sleeve and two sheets of Teflon, which is then heated in a Carver press to 95 ° C, and a force of 3000 pounds is applied to it for 2 minutes.
Then the mold is cooled, -from the compressed material, cut into sheets of a rectangular Form with a size of 2.5x3, 5x xo, 98 inches (6.35x8.89x0.25 cm) and cover them by immersion in an EVA-toluene solution. After
Drying the sheets with a heated Carver press is coated on both sides with an EVA film — polyethylene, polyethylene, and 0.0025 inch (0.00635 cm). Four holes with a diameter of 2.5 i are punched in each sheet.
ten
Separate sheets are placed in water at 4 ° C with constant stirring, and the release is determined for 7 days by spectrophotometric analysis of the solutions at 260 nm. The data obtained when using the device for rapid release of ampicillin gives G:, G in table. ten.
EXAMPLE 9, 1g of a typical device 64.63 g of Sstastic 382 elastomer of medical quality (Sow Corning) and 0.64 g of β-estradiol are interdetermined in a weighed cup. Mix the mixture with a spatula for 10 min. vulcanizing agent, tin octoate (Dow Corging, catalyst M) is added to the mixture until the total amount of vulcanizing substance reaches 0.142 g. The mixture is stirred for another 10 minutes and then poured into a plastic form with azmer 0.1x4x6 inches (, 0.254 x 10.16 x15.24 cm). The form containing the mixture is placed in an evacuated oven to remove air bubbles from the mixture, and then sealed with a gshastik plate. The plate and the form are held together with two metal plates fastened with a series of screws. Mixture in the form is held at 38 ° C. for 24 hours.
The device is removed from the mold and coated with a film of a mixture of EVA - polyethylene using medical glue type A (LOU Corning). The second sheet with an EVA-polyethylene blend is attached to this device using the procedure of Example 9. The devices are punched into 96 holes with a diameter of 0.088 inch (2.24 mm). Data on the rate of drug release from a layered plastic product is given in Table 11.
20
25
thirty
35
40
ten
with
602389 10
EXAMPLE 10 An in vitro release rate from a device prepared in Example 6 is examined, but the material after the extruder is coated by dipping in a 10% solution of EVA in toluene, and then cut into 8.15-inch sheets (20 , 17 cm) and a width of 3.72 inches (9.45 cm). The sheets obtained in this way have open face edges. Thirty-nine holes with a diameter of 2.7 mm are punched into each sheet.
These in vitro release rates determined by the procedure of Example 2 are given in Table. 12.

Forms of invention

权利要求:
Claims (3)
[1]
1. A device for the sustained release of a medicinal substance in the cicatricial-reticular part of the stomach of ruminants, containing a core sheet with a medicinal substance dispersed in it, coated on both sides with polymer films not permeable to the medicinal substance and the liquid of the cicatricial-reticular part of the stomach of ruminants characterized in that, in order to increase the accuracy of controlling the release of the drug substance, through holes are made in polymer films and cores.
[2]
2. The device according to claim 1, wherein the through-holes are round.
[3]
3. The device according to claim 1, wherein the end walls of the core sheet are coated with polymer films that are not permeable to the medicinal substance and fluids of the scar-mesh section of the stomach of ruminants.
Table 2
Note. The average amount of moranthel citrate in the device is 19.10 g, and the average core layer thickness is 0.041. inch (1.6 mm).
Device
amount
1 P2
2-, 1010
3, 1001 204
51000.5
6405
75050
825
960З
10405
 five
Device weight of the core, g | Moranteltsntrat, g
39,7323,84
2 40.18 24.11 4-O-JA24.46,.,.
Note. The average tolgcin core is 0.093 in. (0.236 cm).
  3 b
Time, day The content of accumulated morantelcitrate., Mg, in the device
 G ---
123
 - - --- - “--- - - -i -.- -. J
Z728.3730,0102 8
5,1271,0275,9242 4
8.1372.9371.6354, l
1,0627.3635.8586.3
22,1790,4778,0705,5
0,01186,01145,01094 O
  1810,01752,0i627 o
Time, day The average number of liberated; in the afternoon I Morantel (as a basis), g
- - -. -. .T1 D. -t „,„ ,,
71.12 ± 5.6%
. 1.88 + 5.1%
21. 2,72 + 5,0%
27 3.40 + 4.6%
t a b l Ti c and 4
Makoperperfopatsm
Diameter, mm
160238916
 2 C 8
days I The average number of released I Morantel (as a basis), g
"-..." ,, "in ....." .В ™, i .......,
2.89
. 5.46
7.38
9.02
10.80
10.90
 b l and c a 9,
days The amount of the released extra- 1 diol, mg
17
160238918
Table 11

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1602389A3|1990-10-23|Device for prolonged release of medicinal substance in stomach of ruminants

---

US4601893A|1986-07-22|Laminate device for controlled and prolonged release of substances to an ambient environment and method of use

---

US4756314A|1988-07-12|Sweat collection patch

---

Gehr et al.1981|Design of the mammalian respiratory system. V. Scaling morphometric pulmonary diffusing capacity to body mass: wild and domestic mammals

---

KR950010144B1|1995-09-11|Process for preparing pulsed drug delivery device

---

US5139023A|1992-08-18|Apparatus and method for noninvasive blood glucose monitoring

---

KR900007500B1|1990-10-11|Active agent dispenser

---

DK162876B|1991-12-23|MICROFILE SEALED NITROGLYCEROL PAD FOR TRANSDERMAL NITROGLYCEROL ADMINISTRATION

---

Mutimer et al.1956|Modern ointment base technology II. Comparative evaluation of bases

---

CN1016760B|1992-05-27|Hypersensitivity test means

---

EP0356382A2|1990-02-28|Multilayer plaster

---

CH667589A5|1988-10-31|DELIVERY DEVICE, TRAINED FOR THE PROGRAMMED DELIVERY OF ACTIVE SUBSTANCES TO AN APPLICATION MILE, CONTAINING A MEDICINAL PRODUCT FORMULA.

---

DE3534981A1|1986-04-10|FILM-LIKE PREPARATION

---

JP2001505108A|2001-04-17|Method for producing a disc-shaped molded body containing an active ingredient with less waste and a percutaneous absorption treatment system including the same

---

JP2002212061A|2002-07-31|Process and system for delivery of controlled-release drug

---

Sasaki1977|Measurement of tritiated thymidine labeling index by incubation in vitro of surgically removed cervical cancer

---

Prasanna et al.2012|Design, evaluation and in vitro-in vivo correlation of glibenclamide buccoadhesive films

---

PL90109B1|1977-01-31|

---

WO2004037160A2|2004-05-06|In vitro test for studying compound predicting pharmacologic and/or pharmacokinetic and/or pharmacodynamic parameters of a compound

---

Kirsch et al.1988|An in vivo chemotaxis assay in the dog trachea: evidence for chemotactic activity of 8, 15-diHETE

---

El-Gendy et al.2009|Transdermal delivery of salbutamol sulphate: Formulation and evaluation

---

CN108926549A|2018-12-04|Rivastigmine gel emplastrum and preparation method thereof

---

US4814174A|1989-03-21|Transdermal laminated pharamaceutical compositions having prolonged effect and process for the preparation thereof

---

WO2017146320A1|2017-08-31|Vegetable starch paper mask sheet containing water

---

US5433958A|1995-07-18|Pharmaceutical dosage unit for rectal administration

同族专利:

---

公开号 | 公开日

---

ZW1785A1|1985-05-08|

---

ZA85933B|1986-09-24|

---

AU548349B2|1985-12-05|

---

NZ211053A|1987-06-30|

---

EP0153070B1|1991-05-08|

---

DK55385A|1985-09-19|

---

ES8605672A1|1986-04-01|

---

DK55385D0|1985-02-07|

---

IN162525B|1988-06-04|

---

YU18885A|1988-02-29|

---

HU201241B|1990-10-28|

---

IE850299L|1985-08-08|

---

KR880000431B1|1988-03-24|

---

BR8500551A|1985-09-24|

---

DE3582738D1|1991-06-13|

---

PT79929A|1985-03-01|

---

AT63219T|1991-05-15|

---

ES540130A0|1986-04-01|

---

EP0153070A3|1987-07-15|

---

NO171146B|1992-10-26|

---

FI850518L|1985-08-09|

---

HUT41257A|1987-04-28|

---

FI85326C|1992-04-10|

---

PL150560B1|1990-06-30|

---

GR850334B|1985-06-06|

---

DK164476C|1992-11-16|

---

EG16774A|1991-11-30|

---

UA6341A1|1994-12-29|

---

MX163557B|1992-05-29|

---

DD231984A5|1986-01-15|

---

YU45231B|1992-05-28|

---

IL74263D0|1985-05-31|

---

KR850005940A|1985-09-28|

---

CA1237982A|1988-06-14|

---

PH21485A|1987-11-10|

---

FI85326B|1991-12-31|

---

JPH0442365B2|1992-07-13|

---

ES291052U|1986-04-16|

---

JPS60190709A|1985-09-28|

---

PT79929B|1987-02-02|

---

CN85102106A|1987-01-31|

---

NO850469L|1985-08-09|

---

DK164476B|1992-07-06|

---

IL74263A|1990-08-31|

---

IE57740B1|1993-03-24|

---

AU3852585A|1985-08-15|

---

EP0153070A2|1985-08-28|

---

NO171146C|1993-02-03|

---

CN85102106B|1988-09-14|

---

ES291052Y|1986-12-01|

---

PL251907A1|1987-11-02|

---

FI850518A0|1985-02-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3113076A|1956-07-03|1963-12-03|Henry R Jacobs|Medicinal tablets|

---

AU454482B2|1970-11-05|1974-10-15|Alza Corporation|Drug-delivery system|

---

DK156375C|1978-11-07|1990-03-05|Pfizer|PREPARATIONS FOR ORAL ADMINISTRATION FOR DRUGS WITH LONG-TERM MEDICINAL DELIVERY|

---

EP0021758B1|1979-06-27|1984-04-04|Beecham Group Plc|Veterinary preparations for ruminant animals|US4661388A|1985-01-24|1987-04-28|Minnesota Mining And Manufacturing Company|Pad fragrance sampling device|

---

US4663147A|1985-09-03|1987-05-05|International Minerals & Chemical Corp.|Disc-like sustained release formulation|

---

US4735738A|1985-10-21|1988-04-05|The Procter & Gamble Company|Article with laminated paper orientation for improved fabric softening|

---

US4816262A|1986-08-28|1989-03-28|Universite De Montreal|Controlled release tablet|

---

US4830860A|1986-10-30|1989-05-16|Pfizer Inc.|Stressed polymeric device for controlled release of a substance to an ambient environment|

---

US4792448A|1987-06-11|1988-12-20|Pfizer Inc.|Generic zero order controlled drug delivery system|

---

EP0334516A3|1988-03-21|1991-07-03|Pfizer Inc.|Method for enhancing the unrolling of a rolled matrix device|

---

US4861596A|1988-03-21|1989-08-29|Pfizer Inc.|Rolled matrix device having enhanced ability to unroll and method for its production|

---

GB8815968D0|1988-07-05|1988-08-10|Pfizer Ltd|Veterinary devices|

---

GB8820242D0|1988-08-25|1988-09-28|Kent B E|Sustained release device|

---

FR2658827B1|1990-02-27|1993-12-17|Rhone Poulenc Agrochimie|AGRICULTURAL BIOLOGICAL ACTION SILICON SOLID COMPOSITIONS.|

---

AUPQ573300A0|2000-02-21|2000-03-16|Australian Nuclear Science & Technology Organisation|Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use|

---

TR201902010T4|2006-01-18|2019-03-21|Intec Pharma Ltd|Delivery device for oral administration of an agent.|

---

CN101505696B|2006-06-21|2012-11-14|庄臣及庄臣视力保护公司|Punctal plugs for the delivery of active agents|

---

EP2797582B1|2011-12-30|2019-03-13|Kibur Medical, Inc.|Implantable devices and methods for the evaluation of active agent|

---

JP6348330B2|2014-04-22|2018-06-27|株式会社テックコーポレーション|Hydrogen discharger, hydrogen gas supply method, and hydrogen release system|

---

CN106237338A|2016-09-05|2016-12-21|四川大学|A kind of method preparing biostromal degraded macromolecular drug release material|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US57795084A| true| 1984-02-08|1984-02-08|

---

CN85102106A|CN85102106B|1984-02-08|1985-04-01|Lminate device for controlled and prolonged release of substances to an ambient environment|LV931166A| LV5396A3|1984-02-08|1993-10-22|The device for long-lasting administration of a medicament relies on the rifle of the animal|